OneSource Specialty Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of OneSource Specialty Pharma reported to Rs 10.49 crore in the quarter ended September 2025 as against net loss of Rs 42.08 crore during the previous quarter ended September 2024. Sales rose 12.49% to Rs 375.76 crore in the quarter ended September 2025 as against Rs 334.05 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 11 November 2025.

Powered by Capital Market - Live News

OneSource Specialty Pharma announced that the 18th Annual General Meeting(AGM) of the company will be held on 22 September 2025.

Powered by Capital Market - Live News

The Board of OneSource Specialty Pharma at its meeting held on 04 August 2025 has given their in-principle approval to evaluate potential acquisition of the Sterile Injectable CDMO and CMO businesses of Steriscience and Carbapenem facility of Brooks Steriscience.

The potential transaction, if finalised and consummated, will bring in the following facilities into OneSource:

- USFDA-approved sterile fill-finish manufacturing facility in Warsaw, Poland, with the ability to expand capacity for drug-device combination products for our global partners. This site serves marquee global players and several IP-led products. ?h

- An integrated, state-of-the-art, USFDA-approved carbapenem facility in Vadodara, India operated under the name of Brooks Steriscience.

Steriscience SG and Brooks Steriscience Limited are majorly owned directly/ indirectly by the Promoters of the Company.

Powered by Capital Market - Live News